Format

Send to

Choose Destination
Br J Cancer. 2012 Apr 10;106(8):1374-8. doi: 10.1038/bjc.2012.71. Epub 2012 Mar 15.

Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer.

Author information

1
Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030-4009, USA. cgarrett@mdanderson.org

Abstract

BACKGROUND:

Patients with type II diabetes mellitus (DM) have an increased risk of adenomatous colorectal (CRC) polyps and CRC cancer. The use of the anti-hyperglycemic agent metformin is associated with a reduced incidence of cancer-related deaths.

METHODS:

We retrospectively evaluated the medical records of 4758 patients seen at a single institution and determined that 424 patients were identified by their physicians as having type II DM and CRC cancer. Data were subsequently acquired determining the subject's age, body mass index (BMI), and disease date of diagnosis, stage, site of cancer, treatment, and survival.

RESULTS:

Patients with type II DM and CRC cancer treated with metformin as one of their diabetic medications had a survival of 76.9 months (95% CI=61.4-102.4) as compared with 56.9 months in those patients not treated with metformin (95% CI=44.8-68.8), P=0.048. By using a multivariable Cox regression model adjusted for age, sex, race, BMI, and initial stage of disease, we demonstrated that type II diabetic patients treated with metformin had a 30% improvement in overall survival (OS) when compared with diabetic patients treated with other diabetic agents.

CONCLUSION:

Colorectal cancer patients with DM treated with metformin as part of their diabetic therapy appear to have a superior OS.

PMID:
22421948
PMCID:
PMC3326682
DOI:
10.1038/bjc.2012.71
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center